Feature ArticlesImproving Evaluation and Treatment of Hyperbilirubinemia in Late Preterm InfantsBrown, Sheila A. DNP; Waldrop, Julee DNP; D'Auria, Jennifer PhD; Haushalter, Jamie MSNAuthor Information University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, North Carolina (Maj Brown and Drs Waldrop and D'Auria); and University of North Carolina Children's Hospital Newborn Nursery, Chapel Hill, North Carolina (Ms Haushalter). Corresponding Author: Julee Waldrop, DNP, University of North Carolina at Chapel Hill School of Nursing, CB#7460, Chapel Hill, NC 27599 ([email protected]). Disclosure: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Each author has indicated that he or she has met the journal's requirements for Authorship. Submitted for publication: June 28, 2019; accepted for publication: November 24, 2019. The Journal of Perinatal & Neonatal Nursing: October/December 2020 - Volume 34 - Issue 4 - p 346-351 doi: 10.1097/JPN.0000000000000523 Buy Metrics Abstract Late preterm (LPT) infants are at an increased risk for hyperbilirubinemia. Accurate identification and early treatment are needed for optimal health outcomes. In a newborn nursery at an academic medical center, bilirubin levels were drawn at 24 hours of life, per protocol. These infants were rarely treated at this time. Rather, predischarge bilirubin levels (at about 48 hours of life) would indicate treatment, often leading to increased length of hospital stay. The practice change evaluation was conducted using retrospective medical record review. Practice change to test serum bilirubin levels at 36 hours of life rather than 24 hours of life. Compliance with the practice change was achieved (P < .05). More LPT infants were identified and treated for hyperbilirubinemia without an increase in length of stay. Readmissions for hyperbilirubinemia and blood draw rates also declined. Although more LPT infants were identified and treated for hyperbilirubinemia, there is room for improvement, and increased adherence to the policy might yield an even greater impact on quality and safety of care surrounding bilirubin management. © 2020 Wolters Kluwer Health, Inc. All rights reserved.